GT Biopharma, Inc. (GTBP) Total Return Calculator with Dividends Reinvested

GT Biopharma, Inc.

Popular:

The total return for GT Biopharma, Inc. (GTBP) stock is -86.26% over the past 12 months. So far it's down 44.17% this year. The 5-year total return is -99.89%, meaning $10,000 invested in GTBP stock 5 years ago would be worth $11 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in GTBP 1 year ago, it would be worth $1,201 today — you'd have lost $8,799.

With Dividends Reinvested$1,201-87.99%

Price Only (No DRIP)$1,201-87.99%

Period2025-06-30 → 2026-06-26

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in GTBP

1Y$1,374-$8,626 (-86.3%)-86.3% CAGR

3Y$486-$9,514 (-95.1%)-63.5% CAGR

5Y$11-$9,989 (-99.9%)-74.6% CAGR

10Y$0-$10,000 (-100.0%)-69.1% CAGR

15Y$0-$10,000 (-100.0%)-56.3% CAGR

20Y$0-$10,000 (-100.0%)-46.3% CAGR

30Y$0-$10,000 (-100.0%)-33.9% CAGR

GT Biopharma, Inc. did not pay dividends during this period. Total return = price return.

Loading GTBP total return...

As of 2026-06-29

Performance Summary

Best Year+330.41%2020

Worst Year-89.11%2019

Max Drawdown-92.84%2025-06-26 → 2026-04-29

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-44.17%	—	-47.37%	+3.19 pp	$5,583
1Y	-86.26%	-86.26%	-88.68%	+2.42 pp	$1,374
3Y	-95.14%	-63.50%	-95.42%	+0.28 pp	$486
5Y	-99.89%	-74.56%	-99.91%	+0.02 pp	$11
10Y	-100.00%	-69.08%	-100.00%	—	$0
15Y	-100.00%	-56.33%	-100.00%	—	$0
20Y	-100.00%	-46.28%	-100.00%	—	$0
30Y	-100.00%	-33.92%	-100.00%	—	$0

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-41.49%	-41.49%	—	+0.41%	-41.9pp
2025	-73.30%	-73.30%	—	+16.64%	-89.9pp
2024	-60.13%	-60.13%	—	+24.00%	-84.1pp
2023	-75.00%	-75.00%	—	+24.81%	-99.8pp
2022	-72.24%	-72.24%	—	-19.95%	-52.3pp

GTBP underperformed the S&P 500 by 107.10pp over the past year (-86.26% vs +20.84%).

Loading summary...

GTBP Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
GTBPGT Biopharma, Inc.	$5M	+9.7%	-44.2%	-86.3%	—	-95.1%	-99.9%	-100.0%
IMVTImmunovant, Inc.	$8.0B	+14.8%	+47.5%	+138.9%	—	+98.5%	+247.5%	+284.1%
CRISCuris, Inc.	$61M	-36.8%	-65.3%	-84.5%	—	-97.7%	-99.8%	-99.8%
AGENAgenus Inc.	$126M	-8.7%	-9.6%	-41.6%	—	-91.1%	-97.3%	-96.3%
NKTRNektar Therapeutics	$1.2B	-2.9%	+49.5%	+165.4%	—	+621.1%	-74.6%	-69.9%
ADCTADC Therapeutics S.A.	$130M	-70.9%	-69.5%	-62.3%	—	-46.2%	-95.7%	-96.4%
MGNXMacroGenics, Inc.	$306M	+7.6%	+196.9%	+256.7%	—	-11.6%	-81.7%	-80.2%
FATEFate Therapeutics, Inc.	$245M	-2.3%	+108.1%	+76.1%	—	-58.6%	-97.6%	+9.0%
NKTXNkarta, Inc.	$202M	-7.5%	+54.5%	+65.1%	—	-36.2%	-89.8%	-94.0%
CELCCelcuity Inc.	$4.9B	-25.6%	-4.1%	+693.3%	—	+691.3%	+216.1%	+574.5%
IOVAIovance Biotherapeutics, Inc.	$1.5B	+3.7%	+68.5%	+125.8%	—	-43.6%	-83.7%	-46.0%

Compare:GTBP vs IMVT GTBP vs CRIS GTBP vs AGEN GTBP vs IMVT vs CRIS

About GTBP Dividend Returns

GT Biopharma, Inc. (GTBP) is a dividend-paying stock. When dividends are reinvested through a DRIP (Dividend Reinvestment Plan), they purchase additional shares, which then generate their own dividends—creating a compounding effect that can significantly boost long-term returns.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of GTBP over the past year?

GT Biopharma, Inc. (GTBP) delivered a total return of -86.26% over the past year when dividends are reinvested. The price-only return was -86.26%, meaning dividends contributed an additional 0.00 percentage points to total returns.

Q2How much would $10,000 invested in GTBP be worth today?

A $10,000 investment in GT Biopharma, Inc. one year ago would be worth $1,374 today with dividends reinvested (DRIP). Without reinvesting dividends, the same investment would be worth $1,374. Dividend reinvestment added $0 to the portfolio value.

Q3Does GTBP pay dividends?

Yes, GT Biopharma, Inc. (GTBP) pays dividends. In the last year, GTBP paid approximately $0.04 per share in dividends (9.66% yield). Reinvesting these dividends through a DRIP can significantly boost long-term returns — over 20+ years, dividend compounding can account for 30–50% of total returns for dividend-paying stocks.

Q4Did GTBP beat the S&P 500?

No, GT Biopharma, Inc. (GTBP) underperformed the S&P 500 by 107.10 percentage points over the past year. GTBP delivered a total return of -86.26%, compared to the S&P 500's 20.84%. This means a passive S&P 500 index fund outperformed GTBP by 107.10pp during this period.

Q5What is GTBP's worst drawdown?

GT Biopharma, Inc. (GTBP) experienced a maximum drawdown of -92.84% over the past year, declining from its peak on 2025-06-26 to its trough on 2026-04-29. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is GTBP's long-term total return over 10, 20, or 30 years?

Here are GT Biopharma, Inc. (GTBP)'s long-term returns with dividends reinvested. Over 10 years, the total return is -100.0% (-69.1% CAGR) — $10,000 would have grown to $0. Over 20 years: -100.0% total return (-46.3% CAGR) — $10,000 → $0. Over 30 years: -100.0% total return (-33.9% CAGR) — $10,000 → $0. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was GTBP's best and worst year?

GT Biopharma, Inc.'s best calendar year was 2020 with a total return of 330.4%. Its worst year was 2019 with a total return of -89.1%. This range shows the volatility investors should expect — the difference between the best and worst year is 419.5 percentage points.

How much would $100/month in GTBP be worth today?

Dollar cost averaging calculator · DCA vs lump sum · see how regular investing compounds

Run the Numbers →